Navigation Links
NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease
Date:11/20/2012

NESS ZIONA, Israel, November 20, 2012 /PRNewswire/ --

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

In pre-clinical studies of ND0612, plasma concentrations of levodopa reached straight-line steady state levels. The current Phase I double-blind, dose-escalation trial in young, healthy volunteers will assess ND0612 for safety and tolerability as well as for levodopa and carbidopa steady state plasma levels.

"This first trial of ND0612 in man is a significant step in the development of a new levodopa treatment standard for Parkinson's disease," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "For many years, oral levodopa has been the leading Parkinson's disease drug therapy. However, due to low and erratic oral levodopa bioavailability, advanced Parkinson's patients suffer from debilitating motor complications even under the best current standard of care. Should ND0612 achieve constant levodopa base blood levels, than low, harmful levodopa trough levels would be prevented, the efficacy of current levodopa therapy could be significantly raised and a new standard of care in our ability to treat and reduce motor complications in Parkinson's disease patients may be established."

About Parkinson's Disease

Parkinson's disease affects approximately 6M patients in the world. It is caused by decreasing dopamine signaling in the brain as dopaminergic brain cells die off. Levodopa is the "Gold Standard" therapy for Parkinson's disease and virtually all patients receive it. When administered through the oral route, however, levodopa combined with a decarboxylase inhibitor (carbidopa or benserazide) demonstrates a short clearance half-life and low bioavailability that contribute to motor complications in Parkinson's disease patients. Stable levodopa blood levels have been regarded as the "Holy Grail" of Parkinson's drug therapy, and ways to achieve this have been under investigation for several decades.

About ND0612

ND0612 is based on a proprietary sub-cutaneous levodopa/carbidopa drug formulation that bypasses the digestive tract. It continuously delivers levodopa to achieve straight-line and clinically-significant levodopa blood levels. It also delivers subcutaneous carbidopa to improve the bioavailability of oral levodopa. ND0612 is being developed for administration as an adjunct to oral levodopa via a subcutaneous delivery patch as a new treatment and intervention option in Parkinson's disease treatment. It should reduce off-time and improve the management of motor fluctuations even in patients under the best current standard of care with oral levodopa therapy.

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapies for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well established oral drugs to achieve better efficacy. The company's lead products are ND0611 and ND0612, novel sub-cutaneous drug formulations for the treatment of Parkinson's disease and ND0801, a combination drug for the treatment of ADD/ADHD. Other programs, including those focused at schizophrenia and Alzheimer's disease, are in different stages of development. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact:

Oded S. Lieberman, PhD MBA, Chairman & CEO
oded@neuroderm.com
Tel.: +972-8-946 2729; Cell: +1-617-517-6077


'/>"/>
SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... LOS ANGELES , Feb. 5, 2016  Redwood ... of a new product designed to help women balance ... oral strip delivery technology. Jason Cardiff ... company will be able to help the millions of ... suffer from the effects of imbalanced hormones. Our research ...
(Date:2/5/2016)... 2016  As people age, it is natural to ... screenings and tests that are linked with certain age ... the majority of aging individuals, hearing health is too ... 37.5 million American adults who report some trouble hearing, ... hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... announced the addition of the "Global ... financials" company profile to their offering. ... announced the addition of the "Global ... financials" company profile to their offering. ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... the election of Patrick McDermott as Chairman of the National Board of Directors. Mr. ... as Chairman of the Board,” stated Leslie A. Chambers , APDA President and ...
(Date:2/5/2016)... San Francisco, CA (PRWEB) , ... February 05, ... ... dentist and founder of CitiDent, announces that it is now welcoming ... by Dr. Cheng, CitiDent offers a complete range of oral health care, including ...
(Date:2/5/2016)... ... 2016 , ... Health and wellness is a topic that should concern all ... are experiencing an illness. Migraines are a severe form of a headache and often ... not wish the pain on their worst enemy, the feeling can last for many ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):